EXPOSURE RESPONSE ANALYSIS (PKPD) PREDICTS OPTIMAL EXPOSURE OF PRIDOPIDINE FOR CLINICAL EFFICACY OF FUNCTIONAL CAPACITY

被引：0
|
作者：
Geva, Michal [1 ]
McGarry, Andrew [2 ]
Emek, Noga Gershoni [1 ]
Mehra, Munish [3 ]
Olanow, C. Warren [2 ]
Kieburtz, Karl [2 ]
Hayden, Michael R. [4 ,5 ]
机构：
[1] Prilenia Neurotherapeut, Herzliyya, Israel
[2] Clintrex LLC, Sarasota, FL USA
[3] Tigermed, Gaithersburg, MD USA
[4] Prilenia Neurotherapeut, Naarden, Netherlands
[5] Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC, Canada
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2021年 / 92卷
关键词：
D O I：
10.1136/jnnp-2021-EHDN.85
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
F42
引用
下载
收藏
页码：A36 / A36
页数：1
相关论文
共 50 条
  • [1] Exposure-Response Analysis Demonstrates Predicted Exposure for Clinical Efficacy with Pridopidine 45-mg Bid Dose
    Geva, Michal
    McGarry, Andrew
    Gershoni-Emek, Noga
    Olanow, C. Warren
    Kieburtz, Karl
    Hayden, Michael R.
    NEUROTHERAPEUTICS, 2020, 17 (SUPPL 1) : 22 - 22
  • [2] Population Pharmacokinetics, Efficacy Exposure-Response Analysis
    Chan, Phyllis
    Yu, Jiajie
    Chinn, Leslie
    Prohn, Marita
    Huisman, Jan
    Matzuka, Brett
    Hanley, William
    Tuckwell, Katie
    Quartino, Angelica
    PHARMACEUTICAL RESEARCH, 2020, 37 (02)
  • [3] Comparing the efficacy, exposure, and cost of clinical trial analysis methods
    Oliveira, Andreas
    Romero, Juan M.
    Goldenholz, Daniel M.
    EPILEPSIA, 2019, 60 (12) : E128 - E132
  • [4] An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis
    Per Olsson Gisleskog
    Belén Valenzuela
    Tatiana Scherz
    Michel Burcklen
    Juan Jose Pérez-Ruixo
    Italo Poggesi
    Clinical Pharmacokinetics, 2021, 60 : 1227 - 1237
  • [5] An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis
    Olsson Gisleskog, Per
    Valenzuela, Belen
    Scherz, Tatiana
    Burcklen, Michel
    Jose Perez-Ruixo, Juan
    Poggesi, Italo
    CLINICAL PHARMACOKINETICS, 2021, 60 (09) : 1227 - 1237
  • [6] Exposure-response relationship for the efficacy of fesoterodine
    El-Tahtawy, A.
    Malhotra, B.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 100 - 100
  • [7] Identifying Optimal Dose Combinations of Anticancer Agents via Simultaneous Clinical Exposure-Toxicity and Preclinical Exposure-Efficacy Modeling
    Patel, Mayankbhai
    Kadakia, Ekta
    Zhou, Jilai
    Patel, Chirag
    Venkatakrishnan, Karthik
    Chakravarty, Arijit
    Bottino, Dean
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S68 - S69
  • [8] Elagolix Exposure-Efficacy Analysis
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (04) : 691 - 691
  • [9] Altered Fronto-Limbic Functional Connectivity Predicts Response to Exposure Response Prevention Therapy in OCD in Pediatric OCD
    Cyr, Marilyn
    Pagliaccio, David
    Yanes-Lukin, Paula K.
    Goldberg, Pablo H.
    Fontaine, Martine
    Rynn, Moira
    Marsh, Rachel
    NEUROPSYCHOPHARMACOLOGY, 2020, 45 (SUPPL 1) : 239 - 239
  • [10] Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
    Blumenfeld, Andrew M.
    Goadsby, Peter J.
    Dodick, David W.
    Hutchinson, Susan
    Liu, Chengcheng
    Finnegan, Michelle
    Trugman, Joel M.
    Szegedi, Armin
    HEADACHE, 2021, 61 (03): : 422 - 429
12345